| pubmed-article:8528175 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0037047 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0013018 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0018133 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:8528175 | lifeskim:mentions | umls-concept:C0205280 | lld:lifeskim |
| pubmed-article:8528175 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:8528175 | pubmed:dateCreated | 1996-2-1 | lld:pubmed |
| pubmed-article:8528175 | pubmed:abstractText | The efficacy of the rat monoclonal IgG2b antibody LO-Tact-1 specific for the human interleukin-2 (IL-2) receptor was evaluated for prophylaxis of graft-versus-host disease (GVHD) in patients who received transplants of marrow from HLA-matched sibling donors. Fifteen patients received cyclosporine (CsA) + antibody LO-Tact-1, 0.2 mg/kg/day from day +7 to day +28. Twelve additional patients were administered methotrexate (MTX) + CsA+antibody LO-Tact-1, 0.4 mg/kg/day from day -1 to day +28. The antibody was well tolerated. Engraftment was not affected. GVHD grade > or = II occurred in six of 15 and eight of 12 patients receiving CsA+LO-Tact-1 and MTX+CsA+LO-Tact-1, respectively (P = 0.52). GVHD grade > or = II developed in patients at a median of 32 and 34 days with CsA+LO-Tact-1 and MTX+CsA+LO-Tact-1, respectively (log-rank test, P = 0.57). GVHD contributed to death in four patients who were administered CsA+LO-Tact-1 and in one patient who was administered MTX+CsA+LO-Tact-1. Chronic GVHD occurred in two patients who were treated with CsA+LO-Tact-1 and in two patients treated with MTX+CsA+LO-Tact-1. Throughout therapy, serum levels of LO-Tact-1 ranged from 2 to 10 mg/l. There was no correlation between serum levels of LO-Tact-1 and the occurrence of GVHD. GVHD occurred in 10 patients during LO-Tact-1 prophylaxis. There was no significant difference between relapse or survival rates among the patient groups. We conclude that, while free of adverse effects, monoclonal anti-IL-2 receptor antibody LO-Tact-1 does not improve prophylaxis of GVHD in HLA-matched sibling BMT. | lld:pubmed |
| pubmed-article:8528175 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8528175 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8528175 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8528175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8528175 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8528175 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8528175 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:8528175 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:CornetAA | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:BazinHH | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:MichauxJ LJL | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:FerrantAA | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:StraetmansNN | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:LatinneDD | lld:pubmed |
| pubmed-article:8528175 | pubmed:author | pubmed-author:de la ParraBB | lld:pubmed |
| pubmed-article:8528175 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8528175 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:8528175 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8528175 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8528175 | pubmed:pagination | 577-81 | lld:pubmed |
| pubmed-article:8528175 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:meshHeading | pubmed-meshheading:8528175-... | lld:pubmed |
| pubmed-article:8528175 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8528175 | pubmed:articleTitle | Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1. | lld:pubmed |
| pubmed-article:8528175 | pubmed:affiliation | Department of Hematology, Université Catholique de Louvain, Brussels, Belgium. | lld:pubmed |
| pubmed-article:8528175 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8528175 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8528175 | lld:pubmed |
